Product Highlight - ZEMIGLO

• Renal-Friendly: Once-daily dosing with no adjustment needed in renal impairment¹
• Robust Evidence Base: Backed by 40+ randomized controlled trials plus real-world data in type 2 diabetes.²
• Potent & Consistent Control: Significant HbA1c reduction with improved glycemic variability³

References:
1. Package Insert of Zemiglo.
2. Clinical trials of Gemigliptin registered on ClinicalTrials.gov. (As of 2025.10.01).
3. Kwak SH, et al. Diabetes Obes Metab. 2020 Feb;22(2):173-181.

For healthcare professionals only.

PHARMANIAGA MARKETING SDN BHD
Company No: 198401005734
No. 7 Lorong Keluli 1B, Kawasan Perindustrian Bukit, Raja Selatan, Seksyen 7,
Selangor Darul Ehsan 40000
Tel: (+60) 3342 9999 • Fax: (+60) 3341 7777

Related MIMS Drugs

ZEMIGLO